EMEA-002146-PIP01-17-M04
Key facts
Invented name |
Ibrance
|
Active substance |
Palbociclib
|
Therapeutic area |
Oncology
|
Decision number |
P/0117/2022
|
PIP number |
EMEA-002146-PIP01-17-M04
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of Ewing sarcoma
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 1304 6466 07 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|